Cantor Fitzgerald Reiterates Overweight on Biohaven, Maintains $31 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Biohaven (NYSE:BHVN) and maintained a price target of $31.
July 17, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biohaven's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $31.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Biohaven. The maintained price target of $31 suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100